- Home
- ZNTL vs MAV Comparison
ZNTL vs MAV Comparison
Compare ZNTL & MAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- MAV
- Stock Information
- Founded
- ZNTL 2014
- MAV 2003
- Country
- ZNTL United States
- MAV United States
- Employees
- ZNTL N/A
- MAV N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- MAV Finance Companies
- Sector
- ZNTL Health Care
- MAV Finance
- Exchange
- ZNTL Nasdaq
- MAV Nasdaq
- Market Cap
- ZNTL 227.0M
- MAV 202.6M
- IPO Year
- ZNTL 2020
- MAV N/A
- Fundamental
- Price
- ZNTL $2.25
- MAV $8.56
- Analyst Decision
- ZNTL Buy
- MAV
- Analyst Count
- ZNTL 8
- MAV 0
- Target Price
- ZNTL $10.50
- MAV N/A
- AVG Volume (30 Days)
- ZNTL 1.6M
- MAV 66.2K
- Earning Date
- ZNTL 02-25-2025
- MAV 01-01-0001
- Dividend Yield
- ZNTL N/A
- MAV 4.30%
- EPS Growth
- ZNTL N/A
- MAV N/A
- EPS
- ZNTL N/A
- MAV N/A
- Revenue
- ZNTL $40,560,000.00
- MAV N/A
- Revenue This Year
- ZNTL N/A
- MAV N/A
- Revenue Next Year
- ZNTL N/A
- MAV N/A
- P/E Ratio
- ZNTL N/A
- MAV N/A
- Revenue Growth
- ZNTL N/A
- MAV N/A
- 52 Week Low
- ZNTL $2.16
- MAV $6.37
- 52 Week High
- ZNTL $18.07
- MAV $8.34
- Technical
- Relative Strength Index (RSI)
- ZNTL 32.94
- MAV 50.88
- Support Level
- ZNTL $2.16
- MAV $8.43
- Resistance Level
- ZNTL $2.93
- MAV $8.55
- Average True Range (ATR)
- ZNTL 0.28
- MAV 0.08
- MACD
- ZNTL -0.07
- MAV 0.01
- Stochastic Oscillator
- ZNTL 7.69
- MAV 87.50
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About MAV Pioneer Municipal High Income Advantage Fund Inc.
Pioneer Muni High Income Advantage Tr is a closed-end fund designed to pursue high current income exempt from regular federal income tax and as a secondary objective to seek capital appreciation. It predominantly invests in debt securities and other obligations issued by or on behalf of states, territories, and possessions of the United States and the District of Columbia and their political subdivisions, agencies, and instrumentalities, the interest on which is exempt from regular federal income tax.